Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
10 Demonstrated Tips to Expand Your New Android Cell phone: A Thorough Aide - 2Figure out How to Explore the Infotainment Framework in the Slam 1500.
- 36 Web-based Lawful Administrations: Extensive Surveys and Elements
- 4With more Moon missions on the horizon, avoiding crowding and collisions will be a growing challenge
- 5Innospace's rocket crashes in first commercial launch in Brazil; shares tumble
- Peloton recalls more than 800,000 bikes after broken seat posts injure users
- ByHeart infant formula recall tied to botulism outbreak puts parents on edge
- Ten Awesome Authentic Realities That Will Leave You Interested
- The Solution to Defeating Tarrying: Systems for Expanded Efficiency
- Fireballs and a full moon. Here’s how to see two celestial events this week
- This Overlooked Predator Is Running Out of Time—Why Conservationists Are Racing to Save the Striped Hyena
- How Would You Like to Deal with Your Funds?
- People are getting their news from AI – and it’s altering their views
- Luigi Mangione‘s lawyers say Bondi’s death penalty decision was tainted by conflict of interest
